Georgia is currently home to 1930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Georgia Clinical Research, LLC, 2878 Five Forks Trickum SW, Suite 2A, Lawrenceville, Georgia
Conditions: Post-Bariatric Hypoglycemia
Register for Updates
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
NCT05858320
Recruiting
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Emory University, Grady Hospital, Atlanta, Georgia
Conditions: Heart Failure
Register for Updates
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081
Recruiting
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/02/2025
Locations: Summit Cancer Care PC, Savannah, Georgia
Conditions: Early Breast Cancer
Register for Updates
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT05746559
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/02/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Register for Updates
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry * A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection * Enrollment is open to all genes on the RD Rare Gene List Natural History Study * A prospective, standardized, longitudinal Natural History Study * Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives 1. Genotype Character... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/02/2025
Locations: Emory University, Emory Eye Center, Atlanta, Georgia
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
NCT05423717
Recruiting
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/02/2025
Locations: NeuroTrials Research, Inc., Atlanta, Georgia
Conditions: Insomnia
Register for Updates
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
NCT05421741
Recruiting
This prospective randomized clinical trial will compare outcomes between patients treated primarily with a prophylactic antibiotic coated nail and those treated with traditional standard of care intramedullary (IM) nailing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Atrium Health Navicent, Macon, Georgia
Conditions: Osteomyelitis Tibia, Tibial Fractures, Open tíbia Fracture
Register for Updates
CONVERGE Post-Approval Study (PAS)
NCT05393180
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: Emory Saint Joseph Hopsital, Atlanta, Georgia
Conditions: Chronic Atrial Fibrillation
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Acquired Hemophilia A
Register for Updates
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Winship Cancer Institute of Emory University /ID# 242153, Atlanta, Georgia
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
ALL
Ages:
Between 9 months and 21 years
Trial Updated:
06/02/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates